Video Series

A decade-long window before symptoms invites early intervention, much as cholesterol control prevents heart attacks. Blood biomarkers offer promise, yet false positives and unproven treatment make screening of symptom-free adults premature.

Patient preference for oral therapy, early CNS penetration data, and both positive and negative phase 3 readouts are shaping how clinicians may sequence exon 20-targeted agents.

Serum biomarkers, baseline immunoglobulin testing, and patient preference are reshaping individualized MS care. The panel also imagines a Framingham-style risk score to guide how aggressively to treat.

Lung function alone cannot capture the full toll of a bronchiectasis exacerbation, prompting a closer look at practical severity markers and patient-reported symptom tracking tools.

Early high-efficacy treatment is now common, but the field has not settled how long patients should stay on B-cell depletion. Two randomized strategy trials may clarify who needs which approach.

Alzheimer's disease is now defined biologically as well as clinically, which reveals a long silent phase. Six stages, separated by biomarkers and daily function, replace the older notion of having the disease or not.

With three first-line strategies emerging, differences in toxicity and CNS activity may matter as much as efficacy, while final survival results reinforce the value of the established combination.

Phase 2 data show the all-oral regimen performs comparably to intravenous combinations, while inpatient admissions expose gaps in formularies, medication custody, and reimbursement for oral chemotherapy.

An all-oral regimen is a meaningful advance in newly diagnosed AML, yet early monitoring needs, complex dosing, and patient readiness lead many clinicians to begin cycle 1 intravenously.

As evolving guidelines fold new regimens into category-one recommendations, keeping pace with which combinations qualify as frontline standard has become its own clinical and administrative challenge.

New data challenges a long-standing radiation practice: prophylactic cranial irradiation showed no survival benefit and worse cognitive outcomes, pushing the field toward closer monitoring instead of routine preventive treatment.

Phase 2 data show recombinant AAT-Fc therapy restoring normal functional levels with far fewer infusions than plasma-derived augmentation. Whether those levels translate to clinical benefit will depend on longer studies.

Curing vitiligo isn't currently possible, and Dr. Desai says saying so plainly builds trust. He explains how he sets realistic, patient-specific goals around activity control and repigmentation.

Selecting an IL-5 inhibitor begins with evidence and comorbidities, yet dosing schedule and site of care often determine whether patients can remain on therapy.

Payer acceptance of asthma biologics has improved considerably, yet coverage still varies widely by health system, and plans can override a treatment choice reached through shared decision-making.

Ultra-potent topical steroids remain effective for vitiligo, but not without cost. Dr. Hamzavi weighs atrophy, systemic hormonal effects, and paradoxical hypopigmentation against the benefits of faster repigmentation.

Earlier recognition requires better tools and wider awareness across medicine and the public. Dr. Lev-Tov sees growing investment, research funding, and a loaded drug pipeline as reasons to be optimistic.

Calling HS cosmetic is inaccurate and affects coverage decisions. Dr. Lev-Tov lays out the inflammatory, symptomatic, systemic, and functional evidence that this is a serious medical disease.

Treating MS as a continuum conflicts with phenotype-based coding and payer criteria. The panel describes how those frameworks restrict access for patients who are progressing without recent relapses.

A phase 3 trial of an exon 20-specific oral inhibitor combined with chemotherapy reports improved progression-free survival and response, alongside cytopenias concentrated in the induction phase.

Years of misdiagnosis as asthma or COPD can leave bronchiectasis patients with irreversible lung damage, underscoring the clinical clues physicians need to catch the disease sooner.

Relapsing and progressive biology coexist in every patient, and clinical tools remain blunt. The panel considers biomarkers, treatable comorbidities, and rehabilitation before attributing worsening to MS progression.

Bronchiectasis may have countless underlying causes, but its structural and inflammatory endpoint looks strikingly consistent, a distinction reshaping how the field approaches diagnosis and treatment.

Clinic-based administration, toxicity management, and frequent CNS involvement all add to the burden of this disease, sharpening interest in oral inhibitors built specifically for exon 20 insertions.

Every patient with AML needs comprehensive mutation testing at diagnosis and again at progression, yet even effective targeted and venetoclax-based regimens remain noncurative and carry cumulative toxicity.

Venetoclax combinations have become the backbone of AML therapy for older and unfit patients, but drug interactions, dose modifications, and prior hypomethylating agent exposure complicate real-world use.

With comparable survival benefits and overlapping trial populations, choosing between two frontline immunotherapy regimens increasingly comes down to chemotherapy backbone flexibility and one drug's added indication across both disease stages.

An engineered Fc fusion protein is designed to circulate longer, resist oxidation, and hold levels within the true normal range between infusions, without depending on human plasma.